Parameter
| Biomarker | CD226⁺ B cell | Full name | Cluster of Differentiation 226-positive B lymphocyte | Molecular Type | Subpopulation of immune cells |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Assessment of disease activity and prognosis |
| Disease | Autoimmune Disease (AD) | Disease Subtypes | / | ||
| Organ | Spleen, thymus, lymphoid tissue | Test Sample / Technology Platform | Peripheral blood (flow cytometry) | ||
| Pathobiological Mechanisms | The proportion was significantly elevated in SLE patients and showed a positive correlation with the SLEDAI-2K score and anti-dsDNA antibody titer. | ||||
| Clinical Availability Status | Study validation: The baseline ratio is associated with prognosis 12 months later, with a higher proportion observed in patients with renal involvement. | ||||
| Notes and Dynamics | Provide reference for therapeutic efficacy evaluation and prognosis assessment. | ||||